Compare Moderna, Inc. (MRNA) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

PALL (Aberdeen Physical Palladium Shares ETF) trades at $25.15, showing minimal daily movement with a 0.16% gain. Technical indicators show a bullish trend with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions. The ETF recently underwent a 1:5 stock split effective May 18, 2026, adjusting share structure while maintaining exposure to physical palladium.

PALL offers exposure to palladium's supply-demand dynamics amid current price weakness, with analysts viewing the 47% decline from January 2026 highs as a potential buying opportunity. Key risks include Federal Reserve policy uncertainty and industrial demand fluctuations. The ETF's physical backing provides direct commodity exposure, though palladium's volatility requires careful risk management.